A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

NCT02662712 PHASE1 COMPLETED

The purpose of this study is to evaluate pharmacokinetics and safety data including serious and other adverse events, physical examinations, vital signs, 12-lead electrocardiograms (ECGs) and clinical laboratory results (including biochemistry, hematology, and urine).

Details

Lead sponsor	Janssen Sciences Ireland UC
Phase	PHASE1
Status	COMPLETED
Enrolment	87
Start date	Thu Dec 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy
• Hepatitis, Chronic

Interventions

• JNJ-56136379
• Placebo

Countries

Georgia, France, Malaysia, Belgium, Taiwan, Germany, Moldova, Romania, Bulgaria, Spain